Q4 and Year End 2007 ARYx Therapeutics Earnings Conference Call from Mar 12, 2008 made me remember ATI-5923 which will start phase IIb soon. Maybe it should be included in the future (next generation) oral anticoagulants.
[Added entry for ARYX’s ATI-5923. Please see MNTA ‘ReadMeFirst’ for info on M118.]
General #msg-25160571 Anticoagulant market has large potential (WSJ) #msg-26899903 Anticoagulant market has large potential (graphic) #msg-26451612 Venous thromboembolism is a big, big problem (The Lancet) #msg-18759853 Overview of the new oral anticoagulants #msg-26701803 Technical overview of traditional anticoagulants
Rivaroxaban #msg-25147464 Rivaroxaban bests Lovenox in VTE prevention #msg-24337258 Bayer plans 50,000(!)-patient study
Apixaban #msg-19134406 PFE, BMY ink $1B collaboration #msg-21044973 Apixaban non-inferior to Warfarin in phase-2
Dabigatran #msg-26086079 BI completes enrollment of huge AF trial #msg-25152872 BI starts phase-2 in ACS #msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention
Miscellaneous #msg-27590644 ATI-5923 from ARYX: A safer warfarin? #msg-10569101 Arixtra bests Lovenox in ACS #msg-26298260 Biotinylated Idraparinux causes excess bleeding in AF #msg-22938795 SNY’s AVE5026, Otamixaban (SR123781 dropped Feb-08) #msg-27043616 ART-123 from Artisan Pharma #msg-27187973 Paion’s Solulin completes phase-1 #msg-26385806 NUVO’s NU172 starts phase-1
Market Data 
Markets 
AI
